Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, Nichetti F, Cappelletti MR, Milani M, Strina C, Cervoni V, Barbieri G, Ziglioli N, Dester M, Bianchi GV, De Braud F, Generali D. Sirico M, et al. Among authors: giudici f. Cancers (Basel). 2020 Nov 10;12(11):3314. doi: 10.3390/cancers12113314. Cancers (Basel). 2020. PMID: 33182575 Free PMC article.
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D. Sobhani N, et al. Among authors: giudici f. Mol Biol Rep. 2019 Jun;46(3):2713-2720. doi: 10.1007/s11033-019-04715-9. Epub 2019 Mar 6. Mol Biol Rep. 2019. PMID: 30840203
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
Corona SP, Roviello G, Strina C, Milani M, Madaro S, Zanoni D, Allevi G, Aguggini S, Cappelletti MR, Francaviglia M, Azzini C, Cocconi A, Sirico M, Bortul M, Zanconati F, Giudici F, Rosellini P, Meani F, Pagani O, Generali D. Corona SP, et al. Among authors: giudici f. Breast. 2019 Aug;46:19-24. doi: 10.1016/j.breast.2019.04.004. Epub 2019 Apr 25. Breast. 2019. PMID: 31051411
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S, Paris I, De Placido P, Venturini S, De Laurentis M, Conte P, Juric D, Llombart-Cussac A, Pusztai L, Prat A, Jerusalem G, Di Leo A, Generali D. Schettini F, et al. Among authors: giudici f. J Natl Cancer Inst. 2020 Nov 1;112(11):1089-1097. doi: 10.1093/jnci/djaa071. J Natl Cancer Inst. 2020. PMID: 32407488 Free PMC article.
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment.
Ianza A, Giudici F, Pinello C, Corona SP, Strina C, Bernocchi O, Bortul M, Milani M, Sirico M, Allevi G, Aguggini S, Cocconi A, Azzini C, Dester M, Cervoni V, Bottini A, Cappelletti M, Generali D. Ianza A, et al. Among authors: giudici f. Tumour Biol. 2020 Jun;42(6):1010428320925301. doi: 10.1177/1010428320925301. Tumour Biol. 2020. PMID: 32489146 Free article. Clinical Trial.
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.
Corona SP, Giudici F, Jerusalem G, Ciruelos E, Strina C, Sirico M, Bernocchi O, Milani M, Dester M, Ziglioli N, Barbieri G, Cervoni V, Montemurro F, Generali D. Corona SP, et al. Among authors: giudici f. Oncotarget. 2020 Jun 9;11(23):2172-2181. doi: 10.18632/oncotarget.27612. eCollection 2020 Jun 9. Oncotarget. 2020. PMID: 32577163 Free PMC article.
270 results